Johnson & Johnson (NYSE:JNJ), a global healthcare giant, finds itself at a critical juncture as it navigates a complex landscape of opportunities and challenges. The company's recent performance and ...

Barclays raised the firm’s price target on Johnson & Johnson to $166 from $159 and keeps an Equal Weight rating on the shares. The company ...

One such company is Intuitive Surgical ( ISRG 0.11%). The medical device specialist's market cap currently tops $215 billion, ...

Barclays (LON:BARC) analyst Matt Miksic increased the price target for Johnson & Johnson (NYSE:JNJ) shares, taking it up to ...

HistoSonics, a medical device company backed by Johnson & Johnson’s venture capital arm, is exploring the possibility of a U.S. initial ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/100.sbqKNnJW.js ...

Johnson & Johnson surpassed earnings expectations with strong sales, but it faces challenges ahead due to patent expirations.

Johnson & Johnson, founded in 1886, makes and sells medical devices, pharmaceuticals, and consumer health products. Headquartered in New Brunswick, N.J., the company operates over 250 subsidiary ...

Julie Whytock said she spent 26 weeks in hospital after her cancer diagnosis (Photo: supplied (left) Justin Sullivan/Getty ...

Johnson & Johnson stands alone as a leader across ... closer to 2% annually between 2025 and 2030. We already view the company as undervalued, and if J&J achieves its long-term guidance, there ...

This fall, pharmaceutical and medical technology company Johnson & Johnson announced that a newly created Dallas subsidiary ...

The company discontinued sales of talc-based baby ... Those findings uniformly show the absence of asbestos contamination in Johnson's Baby Powder and the talc sourced for Johnson's Baby Powder.